NASDAQ:CRSP CRISPR Therapeutics (CRSP) Stock Price, News & Analysis $56.09 -0.17 (-0.30%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$56.14 +0.05 (+0.09%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CRISPR Therapeutics Stock (NASDAQ:CRSP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CRISPR Therapeutics alerts:Sign Up Key Stats Today's Range$53.70▼$56.7850-Day Range$36.04▼$68.1452-Week Range$30.04▼$71.13Volume2.99 million shsAverage Volume3.82 million shsMarket Capitalization$4.84 billionP/E RatioN/ADividend YieldN/APrice Target$70.07Consensus RatingModerate Buy Company Overview CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com. Read More CRISPR Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreCRSP MarketRank™: CRISPR Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 440th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingCRISPR Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 9 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageCRISPR Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CRISPR Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CRISPR Therapeutics are expected to grow in the coming year, from ($5.16) to ($4.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CRISPR Therapeutics is -12.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CRISPR Therapeutics is -12.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCRISPR Therapeutics has a P/B Ratio of 2.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CRISPR Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted29.30% of the outstanding shares of CRISPR Therapeutics have been sold short.Short Interest Ratio / Days to CoverCRISPR Therapeutics has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in CRISPR Therapeutics has recently decreased by 0.94%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCRISPR Therapeutics does not currently pay a dividend.Dividend GrowthCRISPR Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted29.30% of the outstanding shares of CRISPR Therapeutics have been sold short.Short Interest Ratio / Days to CoverCRISPR Therapeutics has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in CRISPR Therapeutics has recently decreased by 0.94%, indicating that investor sentiment is improving. News and Social Media3.0 / 5News Sentiment0.45 News SentimentCRISPR Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for CRISPR Therapeutics this week, compared to 11 articles on an average week.Search Interest78 people have searched for CRSP on MarketBeat in the last 30 days. This is an increase of 95% compared to the previous 30 days.MarketBeat Follows50 people have added CRISPR Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 194% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, CRISPR Therapeutics insiders have bought 36,343.09% more of their company's stock than they have sold. Specifically, they have bought $51,499,918.00 in company stock and sold $141,316.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of CRISPR Therapeutics is held by insiders.Percentage Held by Institutions69.20% of the stock of CRISPR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CRISPR Therapeutics' insider trading history. Receive CRSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CRSP Stock News HeadlinesCRISPR Therapeutics AG (NASDAQ:CRSP) Director Simeon George Purchases 989,812 SharesJuly 18, 2025 | insidertrades.comCRISPR Therapeutics (CRSP) Expected to Announce Quarterly Earnings on MondayAugust 3 at 2:17 AM | americanbankingnews.comAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video. | Brownstone Research (Ad)CRISPR Therapeutics (CRSP) Sees 47% Price Increase Over Last QuarterAugust 2 at 5:14 PM | finance.yahoo.comCathie Wood’s ARK buys Prime Medicine, sells CRISPR stockAugust 1 at 2:39 AM | investing.comThe 3 Things That Matter for CRISPR Therapeutics NowJuly 29, 2025 | msn.comJim Cramer Says “CRISPR Can Either Triple or Do Nothing”July 29, 2025 | insidermonkey.comCRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?July 29, 2025 | msn.comSee More Headlines CRSP Stock Analysis - Frequently Asked Questions How have CRSP shares performed this year? CRISPR Therapeutics' stock was trading at $39.36 at the beginning of the year. Since then, CRSP shares have increased by 42.5% and is now trading at $56.09. How were CRISPR Therapeutics' earnings last quarter? CRISPR Therapeutics AG (NASDAQ:CRSP) announced its quarterly earnings data on Tuesday, May, 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by $0.31. The business's revenue was up 71.6% on a year-over-year basis. When did CRISPR Therapeutics IPO? CRISPR Therapeutics (CRSP) raised $75 million in an IPO on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager. Who are CRISPR Therapeutics' major shareholders? Top institutional investors of CRISPR Therapeutics include ARK Investment Management LLC (11.79%), Sumitomo Mitsui Trust Group Inc. (2.80%), IMC Chicago LLC and TD Asset Management Inc (0.26%). Insiders that own company stock include Simeon George, Samarth Kulkarni, James R Kasinger, Julianne Bruno, John Greene, Raju Prasad and Naimish Patel. View institutional ownership trends. How do I buy shares of CRISPR Therapeutics? Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CRISPR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CRISPR Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/06/2025Today8/03/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRSP CIK1674416 Webwww.crisprtx.com Phone(141) 561-3277FaxN/AEmployees460Year FoundedN/APrice Target and Rating Average Price Target for CRISPR Therapeutics$70.07 High Price Target$120.00 Low Price Target$32.00 Potential Upside/Downside+24.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($4.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$366.25 million Net Margins-1,023.64% Pretax Margin-1,013.10% Return on Equity-20.08% Return on Assets-17.13% Debt Debt-to-Equity RatioN/A Current Ratio15.64 Quick Ratio15.64 Sales & Book Value Annual Sales$37.31 million Price / Sales129.83 Cash FlowN/A Price / Cash FlowN/A Book Value$22.64 per share Price / Book2.48Miscellaneous Outstanding Shares86,360,000Free Float82,650,000Market Cap$4.84 billion OptionableOptionable Beta1.80 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CRSP) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.